Stock Events

Stock Events

Akero Therapeutics 

€25.55
0
+€0.88+3.57% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
55.24
52W Low
21.1
Volume
-
Avg. Volume
1
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0K4.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap11.75B
Madrigal Pharmaceuticals focuses on metabolic diseases, directly competing in the NASH (non-alcoholic steatohepatitis) space with Akero Therapeutics.
Viking Therapeutics
VKTX
Mkt Cap3.48B
Viking Therapeutics is developing treatments for metabolic and endocrine disorders, including NASH, directly competing with Akero's NASH programs.
Galmed Pharmaceuticals
GLMD
Mkt Cap4.14M
Galmed Pharmaceuticals is focused on the development of therapeutics for the treatment of liver diseases, including NASH, competing with Akero.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences has a broad portfolio including NASH treatments, positioning it as a competitor in the same field as Akero.
Agios Pharmaceuticals
AGIO
Mkt Cap1.45B
Agios Pharmaceuticals, though focusing on metabolic disorders and cancer, has interests in areas that could overlap with Akero's NASH focus.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie has a diverse portfolio that includes research in liver diseases, indirectly competing with Akero Therapeutics in the broader liver disease market.

About

Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Andrew Cheng M.D., Ph.D.
Employees
67
Country
United States
ISIN
US00973Y1082

Listings

STU
DE
0K4.STU

0 Comments

Share your thoughts

FAQ

What is Akero Therapeutics stock price today?▼
The current price of 0K4.STU is €25.55 EUR — it has increased by +3.57% in the past 24 hours. Watch Akero Therapeutics stock price performance more closely on the chart.
What is Akero Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Akero Therapeutics stocks are traded under the ticker 0K4.STU.
Is Akero Therapeutics stock price growing?▼
0K4.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Akero Therapeutics has showed a +16.69% increase.
How many employees does Akero Therapeutics have?▼
As of May 04, 2026, the company has 67 employees.
In which sector is Akero Therapeutics located?▼
Akero Therapeutics operates in the Health & Wellness sector.
When did Akero Therapeutics complete a stock split?▼
Akero Therapeutics has not had any recent stock splits.
Where is Akero Therapeutics headquartered?▼
Akero Therapeutics is headquartered in South San Francisco, United States.